Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Maxim Group

Maxim Group started coverage on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report issued on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $4.00 price target on the stock. Context Therapeutics Stock Performance Context Therapeutics stock opened at $1.02 on Monday. The firm has a market cap of […]

Related Keywords

United States , ,Maxim Group ,Context Therapeutics Inc ,Renaissance Technologies ,Geode Capital Management ,Affinity Asset Advisors ,Clear Harbor Asset Management ,Context Therapeutics ,Free Report ,Get Free Report ,Asset Advisors ,Capital Management ,Harbor Asset Management ,Two Sigma Investments ,Sigma Investments ,Therapeutics Inc ,Context Therapeutics Daily ,Nasdaq Cntx ,Fcntx ,Medical ,Initiated Coverage ,